Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, May 25, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that PEI Pharmacare has included AUBAGIO™...
- Approximately 70 per cent of Lemtrada Patients Had Not Received Any Additional Lemtrada Treatment in the Prior Three Years - MISSISSAUGA, ON, April 27, 2015 /CNW/ - Genzyme, a Sanofi company,...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, March 20, 2015 /CNW/- Genzyme, a Sanofi company, announced today that the Newfoundland and Labrador Prescription Drug...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Jan. 16, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that the Manitoba Drug Program has included AUBAGIO™...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Jan. 5, 2015 /CNW/ - Genzyme, a Sanofi company, announced today that the Nova Scotia Drug Program has included AUBAGIO™ ...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Dec. 18, 2014 /CNW/ - Genzyme, a sanofi company, announced today that the Yukon Pharmaceutical Programs have included...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Dec. 11, 2014 /CNW/ - Genzyme, a Sanofi company, announced today that the British Columbia drug program, PharmaCare,...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Dec. 1, 2014 /CNW/ - Genzyme, a sanofi company, announced today that the Alberta Drug Program has included AUBAGIO®...
Once-daily oral medication to be reimbursed for first-line use MISSISSAUGA, ON, Nov. 20, 2014 /CNW/ - Genzyme, a sanofi company, announced today that the Ontario Public Drug Benefit Program has...
Select Canadian clinics to participate in study MISSISSAUGA, ON, Nov. 4, 2014 /CNW/ - Genzyme, a Sanofi company, announced today enrollment of the first patient in a multicenter Phase II clinical...
- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not ...
TORONTO, Feb. 27, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY: Genzyme, a Sanofi company, today announced the Canadian availability of...
MISSISSAUGA, ON, Feb. 27, 2014 /CNW/ - Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™ (alemtuzumab) for the management of adult patients with relapsing-remitting...
MISSISSAUGA, ON, Nov. 20, 2013 /CNW/ - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIO® (teriflunomide) 14 mg as monotherapy for the treatment of patients with...
TORONTO, Feb. 27, 2013 /CNW/ - Genzyme, a Sanofi company, today announced its support of International Rare Disease Day with a series of initiatives meant to call attention to rare diseases as an...
- AUBAGIO 14 mg is the Only Oral MS Therapy to Significantly Delay Progression of Disability Across Two Phase III Studies - TORONTO, Oct. 12, 2012 /CNW/ - Sanofi (EURONEXT: SAN and NYSE: SNY) and its ...
MISSISSAUGA, ON, Oct. 3, 2012 /CNW/ - Genzyme, a Sanofi company fully supports the move by Health Canada to accelerate approval and access to orphan drugs, as well as information through...
TORONTO, Feb. 29, 2012 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced its support of International Rare Disease Day with a series of events to celebrate and...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.